Abstract:Introduction: Peri-ampullary carcinoma is one of the most prevalent pancreatic malignancies in the world.Due to the lack of effective therapies, ever-increasing resistance against drugs, new approaches to effective treatment are warranted.Various factors regulate the drug resistance in cancer cells and metabolism is known to play one of the important roles in carcinogenesis.It is also evident that the phenomenon of metabolic reprogramming promotes tumor progression.So this study was designed to check the role of miRNAs in metabolic reprogramming in peri-ampullary carcinoma.Methodology: Two miRNAs; miR-107 and miR-325 were selected on the basis of existing literature and their role in metabolic reprogramming in different cancers.The expression of these miRNAs and their target genes Pyruvate kinase M2 (PKM2), Lactate dehydrogenase (LDH) and Glutaminase (GLS1) were analyzed in 30 peri-ampullary carcinoma surgical tissue samples along with healthy controls by q-PCR.Also, the circulating levels of miR-107 and miR-326 were assessed by q-PCR in corresponding blood samples (of above tissues) and were compared with circulating levels in 35 healthy controls.miR-107 and miR-326 were transfected individually and in combination in a pancreatic cancer cell line (MiaPaCa) and its effect on cell proliferation and cell survival (by MTT assay) was monitored.Alteration in metabolic response was measured by glucose uptake, lactate production, and glutamine production assay.Results: Significantly decreased expression of miR-107 and miR326 was found in both tissue and blood samples from patients compared to healthy controls.Also, PKM2, LDH, and GLS1 were highly expressed in tumor tissues compared to adjacent normal tissue.In-vitro transfection of miR-107 and mir-326 and co-transfection of mir-107 and mir-326 significantly decreased the expression of metabolic genes (PKM2, LDH, and GLS1).Simultaneously, the glucose uptake, lactate production, and glutamate production significantly decreased in cells transfected with individual miR-107 and 326 and in co-transfection.The transfection results also demonstrated decreased cell proliferation and survival.Conclusion: Our results indicate the role of miR 107 and 326 as the tumor suppressor and miRNA in pancreatic cancer by enhancing the sensitivity of cell towards the treatment.Hence, mir-107 and 326 may prove to be a promising target designing a novel therapeutic approach for the treatment of pancreatic cancer.

Fully‐humanized Bioengineered Mir‐1291 Modulates Key Nutrient Transport and Metabolism to Exert Synergistic Anticancer Effects with Chemotherapeutics

Bioengineered Microrna-1291 Effects on Pancreatic Cancer Cell Proliferation and Xenograft Tumor Growth.

Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models.

Bioengineered Mir‐328‐3p Modulates SLC2A1/GLUT1‐mediated Glucose Uptake and Metabolism to Exert Synergistic Antiproliferative Effects with Chemotherapeutics

Bioengineered Mir-328-3p Modulates GLUT1-mediated Glucose Uptake and Metabolism to Exert Synergistic Antiproliferative Effects with Chemotherapeutics

MicroRNA-222 Controls Human Pancreatic Cancer Cell Line Capan-2 Proliferation by P57 Targeting.

A novel miR-1291-ERRα-CPT1C axis modulates tumor cell proliferation, metabolism and tumorigenesis

Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia Coli is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve Chemosensitivity.

Mir-486 Promotes Capan-2 Pancreatic Cancer Cell Proliferation by Targeting Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN)

Tumor Microenvironment-Modulated Multiple Nanotherapeutic System for Potent Cancer Immunotherapy and Metastasis Inhibition

Mir-3656 Expression Enhances the Chemosensitivity of Pancreatic Cancer to Gemcitabine Through Modulation of the RHOF/EMT Axis.

Microrna-137 Modulates Pancreatic Cancer Cells Tumor Growth, Invasion and Sensitivity to Chemotherapy.

Metformin Inhibited Pancreatic Cancer Growth by Upregulating Mir-143/145 Cluster and Suppressing MAPK Signaling Pathway

MiR-489-3p Reduced Pancreatic Cancer Proliferation and Metastasis by Targeting PKM2 and LDHA Involving Glycolysis

Sa1341 – Pancreatic Acinar Carcinoma Has Distinct Mutation Patterns Than Pdac and Neuroendocrine Tumor

MicroRNA-129-5p Regulates Glycolysis and Cell Proliferation by Targeting the Glucose Transporter SLC2A3 in Gastric Cancer Cells

Mitochondrion-Directed Nanoparticles Loaded with a Natural Compound and a microRNA for Promoting Cancer Cell Death via the Modulation of Tumor Metabolism and Mitochondrial Dynamics

N-methylnicotinamide and nicotinamide N-methyltransferase are associated with microRNA-1291-altered pancreatic carcinoma cell metabolome and suppressed tumorigenesis.

Nanoreactors with Cascade Catalytic Activity Reprogram the Tumor Microenvironment for Enhanced Immunotherapy by Synchronously Regulating Treg and Macrophage Cells

Metabolic Regulation-Mediated Reversion of the Tumor Immunosuppressive Microenvironment for Potentiating Cooperative Metabolic Therapy and Immunotherapy

Nanocomplexes Loaded with Mir-128-3p for Enhancing Chemotherapy Effect of Colorectal Cancer Through Dual-Targeting Silence the Activity of PI3K/AKT and MEK/ERK Pathway.